← Back to Search

Psychedelic

MDMA-Assisted Psychotherapy for PTSD (VALLMDMA_001 Trial)

Phase 2
Recruiting
Led By Shannon Remick, MD
Research Sponsored by VA Loma Linda Health Care System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be 18-55 years old
Participants must be 18-55 years old.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2 months, 12-months follow-up
Awards & highlights

VALLMDMA_001 Trial Summary

This trial is designed to test the feasibility of administering MDMA in conjunction with psychotherapy for combat-related treatment-resistant PTSD in US military veterans.

Who is the study for?
This trial is for US military veterans aged 18-55 with combat-related PTSD that hasn't improved after treatment, enrolled in VA healthcare. They must be generally healthy, not on psychiatric meds (or willing to stop them safely), and agree to avoid alcohol before sessions and certain medications during the study. Pregnant women or those at serious suicide risk are excluded.Check my eligibility
What is being tested?
The trial tests MDMA-assisted psychotherapy's effectiveness for veterans with refractory PTSD over a 12-week period, including three single-dose sessions paired with therapy. The main goal is symptom reduction or remission measured by the Clinician-Administered PTSD Scale (CAPS-5).See study design
What are the potential side effects?
Possible side effects of MDMA may include anxiety, mood changes, headache, fatigue, muscle tension, insomnia, nausea and potential increase in heart rate or blood pressure.

VALLMDMA_001 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check β€œYes” for the criteria below
Select...
I am between 18 and 55 years old.
Select...
I am between 18 and 55 years old.

VALLMDMA_001 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2 months, 12-months follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2 months, 12-months follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in total score of CAPS-5

VALLMDMA_001 Trial Design

1Treatment groups
Experimental Treatment
Group I: Open LabelExperimental Treatment1 Intervention
Participants will receive an initial dose of 80 mg of 3,4-methylenedioxymethamphetamine (MDMA) and an optional supplemental dose of 40 mg MDMA during the first Experimental Session. In the second and third Experimental Sessions, the participant will receive an initial dose of 120 mg MDMA and an optional supplemental dose of 40 mg MDMA.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Midomafetamine
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Lykos TherapeuticsOTHER
41 Previous Clinical Trials
1,629 Total Patients Enrolled
VA Loma Linda Health Care SystemLead Sponsor
9 Previous Clinical Trials
765 Total Patients Enrolled
Multidisciplinary Association for Psychedelic StudiesOTHER
39 Previous Clinical Trials
1,603 Total Patients Enrolled

Media Library

3,4-methylenedioxymethamphetamine (MDMA) (Psychedelic) Clinical Trial Eligibility Overview. Trial Name: NCT04264026 β€” Phase 2
Post-Traumatic Stress Disorder Research Study Groups: Open Label
Post-Traumatic Stress Disorder Clinical Trial 2023: 3,4-methylenedioxymethamphetamine (MDMA) Highlights & Side Effects. Trial Name: NCT04264026 β€” Phase 2
3,4-methylenedioxymethamphetamine (MDMA) (Psychedelic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04264026 β€” Phase 2
Post-Traumatic Stress Disorder Patient Testimony for trial: Trial Name: NCT04264026 β€” Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially take part in this research project?

"This clinical trial is testing a new treatment for stress disorder related to combat. To be eligible, patients must between the ages of 18 and 55. Only 10 individuals will be accepted into the study."

Answered by AI

Can more people still join this experiment?

"The trial is currently recruiting patients, with the most recent update on clinicaltrials.gov being from October 12th, 2022. The first posting was on July 29th, 2021."

Answered by AI

Are people of all ages eligible for this research?

"This study is only open to adults aged 18-55. There are 298 other trials available for minors and 896 clinical studies seniors can participate in."

Answered by AI

What dangers does 3,4-methylenedioxymethamphetamine pose to people?

"3,4-methylenedioxymethamphetamine's safety was estimated to be a 2. Although there is some data supporting its safety, none of it points to the efficacy of this drug."

Answered by AI

How many patients will be participating in this clinical trial?

"That is correct. The most recent information on clinicaltrials.gov indicates that this study began recruitment on 7/29/2021 and is still ongoing. They are looking for a total of 10 patients from 1 site."

Answered by AI

Who else is applying?

What state do they live in?
Georgia
California
How old are they?
65+
18 - 65
What site did they apply to?
VA Loma Linda Health Care System
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

Stuck I have Cptsd.
PatientReceived 2+ prior treatments

How responsive is this trial?

Average response time
  • < 1 Day
Most responsive sites:
  1. VA Loma Linda Health Care System: < 24 hours
Typically responds via
Phone Call
Email
~2 spots leftby Dec 2024